Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2006

01-10-2006 | Article

Association between variants in the genes for adiponectin and its receptors with insulin resistance syndrome (IRS)-related phenotypes in Mexican Americans

Authors: D. K. Richardson, J. Schneider, M. J. Fourcaudot, L. M. Rodriguez, R. Arya, T. D. Dyer, L. Almasy, J. Blangero, M. P. Stern, R. A. DeFronzo, R. Duggirala, C. P. Jenkinson

Published in: Diabetologia | Issue 10/2006

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to examine whether genetic variation in ADIPOQ, ADIPOR1 and ADIPOR2 may contribute to increased susceptibility to components of the insulin resistance syndrome (IRS).

Materials and methods

We genotyped single-nucleotide polymorphisms (SNPs) in ADIPOQ, ADIPOR1 and ADIPOR2 in Mexican American subjects (N=439) and performed an association analysis of IRS-related traits.

Results

Of the eight SNPs examined in the ADIPOQ gene, rs4632532 and rs182052 exhibited significant associations with BMI (p=0.029 and p=0.032), fasting specific insulin (p=0.023 and p=0.026), sum of skin folds (SS) (p=0.0089 and p=0.0084) and homeostasis model assessment of insulin sensitivity (HOMA-%S) (p=0.015 and p=0.016). Two other SNPs, rs266729 and rs2241767, were significantly associated with SS (p=0.036 and p=0.013). SNP rs7539542 of ADIPOR1 was significantly associated with BMI, SS and waist circumference (p=0.025, p=0.047 and p=0.0062). Fourteen of the ADIPOR2 SNPs were found to be significantly (p<0.05) associated with fasting plasma triglyceride concentrations. Four of these SNPs (rs10848569, rs929434, rs3809266 and rs12342) were in high pairwise linkage disequilibrium (r 2=0.99) and were strongly associated with fasting triglyceride levels (p=0.00029, p=0.00016, p=0.00027 and p=0.00021). Adjusting for the effects of BMI and HOMA-%S on triglyceride concentrations increased significance to p=0.000060 for SNP rs929434. Bayesian quantitative trait nucleotide analysis was used to examine all possible models of gene action. Again, SNP rs929434 provided the strongest statistical evidence of an effect on triglyceride concentrations.

Conclusions/interpretation

These results provide evidence for association of SNPs in ADIPOQ and its receptors with multiple IRS-related phenotypes. Specifically, several genetic variants in ADIPOR2 were strongly associated with decreased triglyceride levels.
Literature
1.
DeFronzo RA (1997) Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177–269
2.
Bays H, Mandarino L, DeFronzo RA (2004) Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463–478PubMedCrossRef
3.
Reaven GM (1995) Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473–486PubMed
4.
DeFronzo RA (1997) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 50:191–197PubMedCrossRef
5.
Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zych K, DeFronzo RA (1989) Effect of insulin on oxidative and non-oxidative pathways of glucose and FFA metabolism in NIDDM. Evidence for multiple sites of insulin resistance. J Clin Invest 84:205–213PubMedCrossRef
6.
Bergman RN, Finegood DT, Kahn SE (2002) The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 32:35–45PubMedCrossRef
7.
Arner P (2001) Free fatty acids—do they play a role in insulin resistance? Diabetes Obes Metab 3:11–19PubMedCrossRef
8.
Groop L, Bonadonna R, Simonson DC, Petrides A, Hasan S, DeFronzo RA (1992) Effect of insulin on oxidative and non-oxidative pathways of glucose and free fatty acid metabolism in human obesity. Am J Physiol 263:79–84
9.
McGarry JD (2001) Banting Lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7–18CrossRef
10.
Duggirala R, Blangero J, Almasy L et al (2001) A major locus for fasting insulin concentrations and insulin resistance on chromosome 6q with strong pleiotropic effects on obesity-related phenotypes in nondiabetic Mexican Americans. Am J Hum Genet 68:1149–1164PubMedCrossRef
11.
Duggirala R, Blangero J, Almasy L et al (2000) A major susceptibility locus influencing plasma triglyceride concentrations is located on chromosome 15q in Mexican Americans. Am J Hum Genet 66:1237–1245PubMedCrossRef
12.
Elbein SC (2002) Perspective: the search for genes for type 2 diabetes in the post-genome era. Endocrinology 43:2012–2018CrossRef
13.
McCarthy M (2003) Growing evidence for diabetes susceptibility genes from genome scan data. Curr Diab Rep 3:159–167PubMedCrossRef
14.
Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286–289PubMedCrossRef
15.
Berg AH, Combs TP, Scherer PE (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13:84–89PubMedCrossRef
16.
Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935PubMedCrossRef
17.
Bajaj M, Suraamornkul S, Piper P et al (2004) Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89:200–206PubMedCrossRef
18.
Heilbronn LK, Smith SR, Ravussin E (2003) The insulin-sensitizing role of the fat derived hormone adiponectin. Curr Pharm Des 9:1411–1418PubMedCrossRef
19.
Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946PubMedCrossRef
20.
Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769PubMedCrossRef
21.
Civitarese AE, Jenkinson CP, Richardson DK et al (2004) Adiponectin receptors gene expression and insulin sensitivity in nondiabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia 47:816–820PubMedCrossRef
22.
Gil-Campos M, Canete RR, Gil A (2004) Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 23:963–974PubMedCrossRef
23.
Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295PubMedCrossRef
24.
Nakatani K, Noma K, Nishioka J et al (2005) Adiponectin gene variation associates with the increasing risk of type 2 diabetes in nondiabetic Japanese subjects. Int J Mol Med 15:173–177PubMed
25.
Gu HF, Abulaiti A, Ostenson CG et al (2004) Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians. Diabetes 53:31–S35CrossRef
26.
Zacharova J, Chiasson JL, Laakso M; STOP-NIDDM Study Group (2005) The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 54:893–899PubMedCrossRef
27.
Vozarova de Courten B, Hanson RL, Funahashi T et al (2005) Common polymorphisms in the adiponectin gene ACDC are not associated with diabetes in Pima Indians. Diabetes 54:284–289PubMedCrossRef
28.
Wang H, Zhang H, Jia Y et al (2004) Adiponectin receptor 1 gene (ADIPOR1) as a candidate for type 2 diabetes and insulin resistance. Diabetes 53:2132–2136PubMedCrossRef
29.
Hara K, Horikoshi M, Kitazato H et al (2005) Absence of an association between the polymorphisms in the genes encoding adiponectin receptors and type 2 diabetes. Diabetologia 48:1307–1314PubMedCrossRef
30.
Damcott CM, Ott SH, Pollin TI et al (2005) Genetic variation in adiponectin receptor 1 and adiponectin receptor 2 is associated with type 2 diabetes in the Old Order Amish. Diabetes 54:2245–2250PubMedCrossRef
31.
Stefan N, Machicao F, Staiger H et al (2005) Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 48:2282–2291PubMedCrossRef
32.
Stern MP, Gaskill SP, Hazuda HP, Gardner LI, Haffner SM (1983) Does obesity explain excess prevalence of diabetes among Mexican Americans? Results of the San Antonio Heart Study. Diabetologia 24:272–277PubMedCrossRef
33.
Stern MP, Mitchell BD, Blangero J et al (1996) Evidence for a major gene for type II diabetes and linkage analyses with selected candidate genes in Mexican-Americans. Diabetes 45:563–568PubMedCrossRef
34.
Stern MP, Rosenthal M, Haffner SM, Hazuda HP, Franco LJ (1984) Sex difference in the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans. The San Antonio Heart Study. Am J Epidemiol 120:834–851PubMed
35.
Almasy L, Blangero J (1998) Multipoint quantitative trait linkage analysis in general pedigrees. Am J Hum Genet 62:1198–1211PubMedCrossRef
36.
Abecasis GR, Cookson WOC, Cardon LR (2000) Pedigree tests of transmission disequilibrium. Eur J Hum Genet 8:545–551PubMedCrossRef
37.
Boerwinkle E, Chakraborty R, Sing CF (1986) The use of measured genotype information in the analysis of quantitative phenotypes in man. Ann Hum Genet 50:181–194PubMed
38.
Almasy L, Blangero J (2004) Exploring positional candidate genes: linkage conditional on measured genotype. Behav Genet 34:173–177PubMedCrossRef
39.
Long AD, Lyman RF, Langley CH, Mackay TF (1999) Two sites in the Delta gene region contribute to naturally occurring variation in bristle number in Drosophila melanogaster. Genetics 149:999–1017
40.
41.
Blangero J, Goring HH, Kent JW Jr et al (2005) Quantitative trait nucleotide analysis using Bayesian model selection. Hum Biol 77:541–559PubMedCrossRef
42.
Curran JE, Jowett JB, Elliott KS et al (2005) Genetic variation in selenoprotein S influences inflammatory response. Nat Genet 37:1234–1241PubMedCrossRef
43.
Almasy L, Blangero J (2004) Exploring positional candidate genes: linkage conditional on measured genotype. Behav Genet 34:173–177PubMedCrossRef
44.
Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L (2001) Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875–1881PubMedCrossRef
45.
Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMedCrossRef
46.
Trujillo ME, Scherer PE (2005) Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257:167–175PubMedCrossRef
47.
Chan DC, Watts GF, Ng TW et al (2005) Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 51:578–585PubMedCrossRef
48.
Hamsten A, Silveira A, Boquist S et al (2005) The apolipoprotein CI content of triglyceride-rich lipoproteins independently predicts early atherosclerosis in healthy middle-aged men. J Am Coll Cardiol 45:1013–1017PubMedCrossRef
49.
Staiger H, Kaltenbach S, Staiger K et al (2004) Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 53:2195–2201PubMedCrossRef
50.
Populaire C, Mori Y, Dina C et al (2003) Does the −11377 promoter variant of APM1 gene contribute to the genetic risk for Type 2 diabetes mellitus in Japanese families? Diabetologia 46:443–445PubMed
Metadata
Title
Association between variants in the genes for adiponectin and its receptors with insulin resistance syndrome (IRS)-related phenotypes in Mexican Americans
Authors
D. K. Richardson
J. Schneider
M. J. Fourcaudot
L. M. Rodriguez
R. Arya
T. D. Dyer
L. Almasy
J. Blangero
M. P. Stern
R. A. DeFronzo
R. Duggirala
C. P. Jenkinson
Publication date
01-10-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0384-3

Other articles of this Issue 10/2006

Diabetologia 10/2006 Go to the issue

Article

Differential effects of IRS1 phosphorylated on Ser307 or Ser632 in the induction of insulin resistance by oxidative stress

Article

Hyperinsulinism in mice with heterozygous loss of KATP channels

Article

Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone

Short Communication

A perfusion protocol for highly efficient transduction of intact pancreatic islets of Langerhans

Article

Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter 4

Short Communication

The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits